Beyond Statins: A Smarter, Personalized Strategy to Reduce Cardiovascular Risk

About the Author

I’m a retired neurologist who spent decades managing vascular disease and its consequences—stroke, cognitive decline, and disability. Much of that burden traces back to atherosclerosis.

The science of lipid management has evolved dramatically, but everyday practice and public understanding have not kept pace. This piece distills what matters now: how to reduce risk using the tools we already have.

Summary and Critique of Cholesterol and Cardiovascular Risk by Peter Attia

More than 90 million Americans take a statin. Yet the public debate remains stuck on a narrow question: “Should I take one?”

That’s the wrong question: For many patients at elevated cardiovascular risk, the real issue is not whether to treat, but how to treat effectively and precisely.

Here’s a practical, evidence-based guide to modern lipid management using apoB, Lp(a), and combination therapy—plus a critical look at where personalized approaches add value.

The Conversation Is Outdated

More than 90 million Americans take a statin. Yet the public debate remains stuck on a narrow question: “Should I take one?”

That’s the wrong question.

For many patients at elevated cardiovascular risk, the real issue is not whether to treat—but how to treat effectively and precisely.

The Key Shift: From LDL-C to ApoB

Traditional care focuses on LDL cholesterol (LDL-C). But LDL-C measures the amount of cholesterol, not the number of particles causing damage.

ApoB tells a different story.

* Each atherogenic particle carries one apoB molecule
* ApoB ≈ particle number
* Atherosclerosis is driven by particle penetration, not cholesterol mass

“It’s not how much cholesterol you carry—it’s how many particles are hitting the artery wall.”

This distinction explains why patients with similar LDL-C can have very different risk.

A modern lipid strategy follows a structured sequence:

1. Establish a Full Baseline

Go beyond the standard lipid panel:

* ApoB
* Lipoprotein(a) [Lp(a)]
* Triglycerides
* Metabolic markers (insulin, HbA1c)
* Inflammation (hs-CRP)
* Consider coronary imaging in selected patients

2. Identify Immediate Risks

* Triglycerides >500 mg/dL → pancreatitis risk
* Significant insulin resistance → part of the lipid problem

3. Determine the Underlying Biology

Cholesterol comes from two sources:

* Absorption (gut)
* Synthesis (liver)

Patients differ in which pathway dominates.

4. Match Therapy to Mechanism

* Hyperabsorber → ezetimibe
* Hypersynthesizer → statin
* Mixed → combination from the start

“Wrong drug, wrong pathway = underwhelming results.”

5. Reassess at 6–8 Weeks

Track:

* ApoB (primary target)
* Lipids
* Liver enzymes
* Symptoms
* Metabolic markers

6. Escalate Intelligently

Avoid the common mistake:

Doubling a statin adds only modest benefit but increases side effects.

Instead, layer therapies:

* Statin
* Ezetimibe
* PCSK9 inhibitor
* Bempedoic acid (if needed or statin-intolerant)

Combination therapy can achieve dramatic reductions.

The Expanding Role of Newer Therapies

PCSK9 Inhibitors

These drugs increase LDL receptor recycling and dramatically lower particle burden.

* LDL reduction: ~45–65%
* Proven reduction in cardiovascular events
* Now more accessible and affordable

“These are no longer last-resort drugs—they’re underused tools.”

Lp(a): The Hidden Risk Multiplier

Lipoprotein(a) is:

* Genetically determined
* Common
* Independent of standard lipids

There is no direct treatment yet.

The current strategy:

* Lower apoB aggressively to compensate

Triglycerides and Metabolic Health

Moderate triglyceride elevation often signals insulin resistance.

Key interventions:

* Reduce refined carbohydrates
* Improve metabolic health
* Consider EPA therapy in high-risk patients

What This Framework Gets Right

This approach improves on conventional care in several ways:

* Moves beyond one-size-fits-all statin therapy
* Focuses on clear treatment targets (apoB)
* Integrates metabolic health with lipid management
* Encourages early combination therapy instead of delayed escalation

“Precision beats habit in lipid management.”

Where It Overreaches

Not everything here is ready for routine practice.

1. Sterol Testing Is Not Standard

While biologically appealing, sterol panels:

* Are not widely used
* Lack large-scale outcomes validation
* Add cost and complexity

2. Complexity vs Practicality

Most patients benefit from a simpler pathway:

* Statin → add ezetimibe → add PCSK9 therapy

This approach is already supported by current guidelines.

3. Risk of Over-Engineering Care

Precision medicine is valuable, but not always necessary.

For many patients, aggressive LDL lowering using proven therapies is sufficient.

Bottom Line

This framework highlights an important shift:

* Cardiovascular risk is driven by apoB particles
* Treatment should be goal-directed and adaptive
* Combination therapy is often required

But the key practical takeaway is simpler:

Stop asking whether to treat cholesterol and start asking what target you need and how to reach it efficiently.